| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Payments of transaction costs related to revenue interest purchase agreement | 0 | 0 |
| Net cash provided by financing activities | 4,314 | 48,905 |
| Net decrease in cash, cash equivalents and restricted cash | -75,449 | -6,905 |
| Cash and cash equivalents at beginning of period | 95,290 | - |
| Cash and cash equivalents at end of period | 19,841 | - |
Humacyte, Inc. (HUMAW)
Humacyte, Inc. (HUMAW)